はじめての方へショーケース価格
  1. 米国企業
  2. Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc.NTLA

時価総額
$23.5億
PER
サマリーテーブルに戻る
損益計算書バランスシートキャッシュフロー
2016年
12月31日		2017年
12月31日		2018年
12月31日		2019年
12月31日		2020年
12月31日		2021年
12月31日		2022年
12月31日
Net loss---85-100-134-268-474
Depreciation and amortization-346678
(Gain) loss on disposal of property and equipment-0-0-0-0-0-0
Equity-based compensation7151715204791
Amortization of investment premiums--14-1-8-4
Loss from equity method investment-----1-11
Equity Method Investment, Amount Sold------11
Change in fair value of contingent consideration------13
Research and Development in Process------56
Accounts receivable54-3-3-2-02
Prepaid expenses and other current assets12-029102
Operating lease right-of-use assets----6-6-9-13
Other assets6-1-1-0-0-01
Accounts payable2-00251-5
Accrued expenses3232131716
Deferred revenue---4-2745-31-63
Operating lease liabilities----5-6-9-10
Other long-term liabilities-0-0-0----
Net cash used in operating activities---61-103-50-225-333
Purchases of property and equipment6106741314
Purchases of marketable securities--2552974741,021429
Maturities of marketable securities---329263486648
Proceeds from sale of property and equipment--0---0
Acquired in-process research and development, net of cash acquired of $2871-----45
Investment in Kyverna Therapeutics, Inc.-----3-
Net cash provided by (used in) investing activities---26125-214-551160
Follow On Public Offering----438648338
At The Market Offerings----15145228
Proceeds from issuance of common stock17114129721,1181,818-
Proceeds from options exercised01113124115
Proceeds from Stock Plans-111223
Net cash provided by financing activities--4076372737583
Net increase (decrease) in cash and cash equivalents and restricted cash equivalents----2107-39410
Capital Expenditures Incurred but Not yet Paid3111212
Right Of Use Assets Acquired Under Operating Lease---3264967
Non-cash Trade-in Of Property and Equipment------0